Home > Oncology > SABCS 2021 > Basic and Translational Research > Inducers of ferroptosis are potential drugs to target p53-mutated TNBC cells

Inducers of ferroptosis are potential drugs to target p53-mutated TNBC cells

Presented By
Dr William Tahaney, MD Anderson Cancer Center, TX, USA
Conference
SABCS 2021
Expression of a mutant p53-gene sensitises triple-negative breast cancer (TNBC) cells to death by ferroptosis. The experimental drug ML-162 induces ferroptosis in p53-mutated TNBCs and demonstrated anti-cancer activity in vitro and in vivo. Up to 85% of TNBCs have a p53 mutation as their oncogenic driver. Due to this high frequency of p53 mutations in TNBCs, targeting p53 mutants in a clinical setting could be highly attractive if pathways exist that, when inhibited, will induce the specific death of p53-mutant breast cancer cells, but not p53-wild type breast cells. Dr William Tahaney (MD Anderson Cancer Center, TX, USA) presented first results of the search for these pathways and drugs that can inhibit them [1]. In vitro and in silico drug screens identified 6 potential drugs that inhibit growth of p53-mutant TNBCs but not p53


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on